Tetrabenazine therapy of pediatric hyperkinetic movement disorders
Identifieur interne : 001870 ( PascalFrancis/Checkpoint ); précédent : 001869; suivant : 001871Tetrabenazine therapy of pediatric hyperkinetic movement disorders
Auteurs : Samay Jain [États-Unis] ; Paul E. Greene [États-Unis] ; Steven J. Frucht [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:07-0021727Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tetrabenazine therapy of pediatric hyperkinetic movement disorders</title><author><name sortKey="Jain, Samay" sort="Jain, Samay" uniqKey="Jain S" first="Samay" last="Jain">Samay Jain</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Neurological Institute, The Center for Parkinson's Disease and other Movement Disorders, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Neurological Institute, The Center for Parkinson's Disease and other Movement Disorders, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0021727</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 07-0021727 INIST</idno><idno type="RBID">Pascal:07-0021727</idno><idno type="wicri:Area/PascalFrancis/Corpus">001904</idno><idno type="wicri:Area/PascalFrancis/Curation">001417</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001870</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tetrabenazine therapy of pediatric hyperkinetic movement disorders</title><author><name sortKey="Jain, Samay" sort="Jain, Samay" uniqKey="Jain S" first="Samay" last="Jain">Samay Jain</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Neurological Institute, The Center for Parkinson's Disease and other Movement Disorders, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Neurological Institute, The Center for Parkinson's Disease and other Movement Disorders, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child</term><term>Hyperkinesia</term><term>Nervous system diseases</term><term>Pediatrics</term><term>Tetrabenazine</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Hyperkinésie</term><term>Tétrabénazine</term><term>Traitement</term><term>Enfant</term><term>Pédiatrie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term><term>Pédiatrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>11</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Tetrabenazine therapy of pediatric hyperkinetic movement disorders</s1></fA08><fA11 i1="01" i2="1"><s1>JAIN (Samay)</s1></fA11><fA11 i1="02" i2="1"><s1>GREENE (Paul E.)</s1></fA11><fA11 i1="03" i2="1"><s1>FRUCHT (Steven J.)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Neurological Institute, The Center for Parkinson's Disease and other Movement Disorders, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA20><s1>1966-1972</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000158935070240</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>17 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0021727</s0></fA47><fA60><s1>P</s1><s3>CC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17A01</s0></fC02><fC02 i1="03" i2="X"><s0>002B02Q</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Hyperkinésie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Hyperkinesia</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hiperquinesia</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Tétrabénazine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Tetrabenazine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tetrabenazina</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Enfant</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Child</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Niño</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Pédiatrie</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Pediatrics</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Pediatría</s0><s5>12</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Trouble psychomotricité</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Psychomotor disorder</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Trastorno psicomotriz</s0><s5>38</s5></fC07><fN21><s1>010</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Jain, Samay" sort="Jain, Samay" uniqKey="Jain S" first="Samay" last="Jain">Samay Jain</name></region><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001870 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001870 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:07-0021727
|texte= Tetrabenazine therapy of pediatric hyperkinetic movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |